Amgen (AMGN): Rep. Daniel Meuser (PA09) disclosed a sale $1K–$15K

$1,001–$15,000

Reported range · official band, not an exact amount

190 days

Disclosure lag

Traded

Feb 11, 2025

Disclosed

Aug 20, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 6, 2024CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
2. Dec 26, 2024FDAFDA drug approval: Wezlana
3. Jan 6, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
4. Jan 16, 2025FDAFDA drug approval: Lumakras
5. Jan 16, 2025FDAFDA drug approval: Vectibix
6. Feb 5, 2025InsiderOfficer sold ~$484K of AMGN shares in the open market
7. Feb 7, 2025InsiderOfficer sold ~$7.34M of AMGN shares in the open market
8. Feb 11, 2025InsiderOfficer sold ~$2.59M of AMGN shares in the open market

What came next

1. Feb 18, 2025InsiderOfficer sold ~$146K of AMGN shares in the open market
2. Feb 19, 2025Insider · 3 peopleInsiders: 3 sales (~$5.6M)
3. Feb 21, 2025InsiderOfficer sold ~$7.68M of AMGN shares in the open market
4. Feb 24, 2025CongressDisclosed purchase of AMGN — reported range $15,001 - $50,000
5. Feb 27, 2025FDARecall: Neupogen (filgrastim) For Injection, 300mcg/1 mL, 1 mL Single Dose Vials, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solution - No Preservative…
6. Feb 27, 2025FDARecall: Neupogen (filgrastim) For Injection, 480 mcg/1.6 mL (300 mcg/1 mL), 1.6 mL single Dose Vial, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solutio…
7. Apr 7, 2025FDAFDA drug approval: Amjevita
8. Apr 8, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
9. Apr 11, 2025CongressDisclosed purchase of AMGN — reported range $15,001 - $50,000
10. Apr 15, 2025CongressDisclosed sale of AMGN — reported range $15,001 - $50,000
11. Apr 16, 2025Congress · 1 personMembers of Congress: 2 purchases
12. May 2, 2025InsiderOfficer sold ~$280K of AMGN shares in the open market
13. May 5, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
14. May 14, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
15. May 20, 2025FDAFDA drug approval: Amjevita
16. May 22, 2025FDAFDA drug approval: Prolia
17. Jun 5, 2025InsiderOfficer sold ~$435K of AMGN shares in the open market

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Amgen

For Amgen, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 54 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMGN page.

Other recent filings by Rep. Daniel Meuser (PA09)

• House Clerk periodic transaction report at NVIDIA (NVDA)Oct 14, 2026
• House Clerk periodic transaction report at NVIDIA (NVDA)Jul 2, 2026
• House Clerk periodic transaction report at NVIDIA (NVDA)May 21, 2026
• House Clerk periodic transaction report at NVIDIA (NVDA)Apr 21, 2026
• House Clerk periodic transaction report at NVIDIA (NVDA)Apr 3, 2026

The full history of Rep. Daniel Meuser (PA09) is on the profile page.

How this filing works

• The STOCK Act

Other disclosures at Amgen

• House Clerk periodic transaction reportOct 1, 2026
• House Clerk periodic transaction reportSep 5, 2026
• House Clerk periodic transaction reportSep 5, 2026
• Senate eFD periodic transaction reportSep 2, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its AMGN page.